

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-13 (canceled).

14 (currently amended). A pharmaceutical composition comprising at least one CD23-binding peptide, wherein said peptide is selected from the group consisting of consisting of the amino acid sequence:

Phe-His-Glu-Asn-Trp-Pro-Ser (SEQ ID NO:1);

Phe-His-Glu-Phe-Trp-Pro-Thr (SEQ ID NO:2);

Phe-His-Ser-Gln-Trp-Pro-Asn (SEQ ID NO:3);

Phe-His-Glu-Asn-Trp-Pro (SEQ ID NO:4);

Phe-His-Glu-Asn-Trp-Pro-Thr (SEQ ID NO:5);

Phe-His-Glu-Gln-Trp-Pro-Ser (SEQ ID NO:6);

His-Glu-Asn-Trp-Pro-Ser (SEQ ID NO:7);

His-Lys-Asn-Trp-Pro-Ser (SEQ ID NO:8);

His-Glu-Asn-Trp-Pro-Ser-Phe (SEQ ID NO:9);

Phe-His-Lys-Pro-Trp-Arg-Ala (SEQ ID NO:10);

His-Glu-Asn-Trp-Lys-Ser (SEQ ID NO:31);

His-Glu-Asn-Trp-Xaa-Ser (SEQ ID NO:32);

His-Glu-Asn-Trp-Gly-Ser (SEQ ID NO:34);

His-Glu-Asn-Trp-Glu-Ser (SEQ ID NO:35);

Phe-His-Glu-Ala-Trp-Pro-Ser (SEQ ID NO:40);

~~Phe His Glu Asn Trp Xaa Ser~~ (SEQ ID NO:43);
~~His Glu Asn Ala Pro Ser~~ (SEQ ID NO:53);
~~His Glu Asn Trp Ser~~ (SEQ ID NO:54);
~~G[allyl] N W G[allyl]~~ (SEQ ID NO:55);
~~NH₂ G[allyl] N W G[allyl]~~ (SEQ ID NO:56);
~~Ac-wn CO₂H~~ (SEQ ID NO:57);
~~Ac-n-w CO₂H~~ (SEQ ID NO:58);
~~Ac-N-W Beta A CO₂H~~ (SEQ ID NO:60); and
~~H E N W P CONH₂~~ (SEQ ID NO:61);
and a pharmaceutically acceptable carrier.

15-39 (canceled).

40 (previously presented). The peptide according to Claim 59 having a specific binding to CD23 of at least about 10⁻⁶ M.

41-57(canceled).

58 (previously presented). The composition according to claim 14 wherein said peptide comprises at least one amino acid which is D-isomer.

59 (currently amended). A CD23-binding peptide, wherein said peptide comprises the amino acid sequence of any one of SEQ ID NOs: 2 to 10, 31, 32, 34, 35, 40, 43 and 53-61 consists of:

Phe-His-Glu-Phe-Trp-Pro-Thr (SEQ ID NO:2);
Phe-His-Ser-Gln-Trp-Pro-Asn (SEQ ID NO:3);
Phe-His-Glu-Asn-Trp-Pro (SEQ ID NO:4);
Phe-His-Glu-Asn-Trp-Pro-Thr (SEQ ID NO:5);
Phe-His-Glu-Gln-Trp-Pro-Ser (SEQ ID NO:6);
His-Glu-Asn-Trp-Pro-Ser (SEQ ID NO:7);
His-Lys-Asn-Trp-Pro-Ser (SEQ ID NO:8);
His-Glu-Asn-Trp-Pro-Ser-Phe (SEQ ID NO:9);
Phe-His-Lys-Pro-Trp-Arg-Ala (SEQ ID NO:10);
His-Glu-Asn-Trp-Lys-Ser (SEQ ID NO:31);
His-Glu-Asn-Trp-Xaa-Ser (SEQ ID NO:32);
His-Glu-Asn-Trp-Gly-Ser (SEQ ID NO:34);
His-Glu-Asn-Trp-Glu-Ser (SEQ ID NO:35);
Phe-His-Glu-Ala-Trp-Pro-Ser (SEQ ID NO:40);
Phe-His-Glu-Asn-Trp-Xaa-Ser (SEQ ID NO:43);
His-Glu-Asn-Ala-Pro-Ser (SEQ ID NO:53);
His-Glu-Asn-Trp-Ser (SEQ ID NO:54);
G[allyl-] N W G[allyl-] (SEQ ID NO:55);
NH₂ Grallyl-] N W G[allyl-] (SEQ ID NO:56);
Ac wn CO₂H (SEQ ID NO:57);

Ac NW CO₂H (SEQ ID NO:58);
Ac n w CO₂H (SEQ IDNO:59);
Ac N W BetaA CO₂H (SEQ ID NO:60); or
H E N W P CONH₂ (SEQ ID NO:61).

60 (previously presented). The peptide according to claim 59 comprising at least one amino acid which is a D-isomer, an acylated N-terminus, and acetylated N-terminus or amidated C-terminus.

61 (currently amended). The composition according to Claim 14 wherein said peptide comprises ~~an~~ the N-terminus and wherein ~~said~~ the N-terminus of said peptide is acylated.

62 (currently amended). The composition according to Claim 61 wherein ~~said~~ the N-terminus of said peptide is acetylated.

63 (currently amended). The composition according to Claim 14 wherein said peptide comprises a C-terminus and wherein ~~said~~ the C-terminus of said peptide is amidated.

64 (previously presented). A peptide of claim 59 wherein said peptide is labeled with a detectable marker.